| Title |
Current concepts in multiple sclerosis therapy
|
|---|---|
| Published in |
Degenerative Neurological and Neuromuscular Disease, September 2017
|
| DOI | 10.2147/dnnd.s109251 |
| Pubmed ID | |
| Authors |
Leslie Sedal, Antony Winkel, Joshua Laing, Lai Yin Law, Elizabeth McDonald |
| Abstract |
Over the past 20 years, the available therapies for multiple sclerosis have expanded exponentially. With several more agents likely to be approved for public funding in Australia in the next 12 months on top of the existing multitude of Australian Pharmaceutical Benefits Scheme-subsidized therapies, the choice is becoming even more complex. This review summarizes the current state of available therapies and anticipates likely future directions, including an important focus on contemporary symptom management. For each agent, the major trials, side effects, and clinical utility are summarized, with a particular focus on the Australian experience of these therapies. It is hoped this review provides an up-to-date reference of the exciting current state of multiple sclerosis therapy. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
| Members of the public | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 16% |
| Student > Bachelor | 6 | 12% |
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Doctoral Student | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 18 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 16% |
| Medicine and Dentistry | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Neuroscience | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 23 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2018.
All research outputs
#6,438,690
of 25,584,565 outputs
Outputs from Degenerative Neurological and Neuromuscular Disease
#33
of 89 outputs
Outputs of similar age
#91,619
of 324,978 outputs
Outputs of similar age from Degenerative Neurological and Neuromuscular Disease
#1
of 1 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 89 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.9. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them